$6.07
1.85% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Enanta Pharmaceuticals, Inc. Stock price

$6.07
+0.84 16.06% 1M
-3.01 33.15% 6M
+0.32 5.57% YTD
-6.40 51.32% 1Y
-35.80 85.50% 3Y
-50.02 89.18% 5Y
-34.48 85.03% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.11 1.85%
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Key metrics

Market capitalization $129.76m
Enterprise Value $152.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.37
P/S ratio (TTM) P/S ratio 2.01
P/B ratio (TTM) P/B ratio 1.39
Revenue growth (TTM) Revenue growth -11.55%
Revenue (TTM) Revenue $64.46m
EBIT (operating result TTM) EBIT $-102.11m
Free Cash Flow (TTM) Free Cash Flow $-82.24m
Cash position $193.38m
EPS (TTM) EPS $-4.54
P/E forward negative
P/S forward 2.10
EV/Sales forward 2.47
Short interest 14.73%
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

4x Buy
67%
1x Hold
17%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
17%
Sell
17%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
64 64
12% 12%
100%
- Direct Costs 3.17 3.17
23% 23%
5%
61 61
13% 13%
95%
- Selling and Administrative Expenses 45 45
13% 13%
70%
- Research and Development Expense 115 115
24% 24%
179%
-99 -99
26% 26%
-153%
- Depreciation and Amortization 3.17 3.17
23% 23%
5%
EBIT (Operating Income) EBIT -102 -102
25% 25%
-158%
Net Profit -96 -96
27% 27%
-150%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
8 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025. “Throughout the fiscal second quarter, Enanta remained squarely focused on executing across our virolo...
Neutral
Business Wire
about one month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025.
Neutral
Business Wire
2 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET....
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today